Are we closer to having drugs to treat muscle wasting disease?
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The two most common muscle wasting diseases in adults are sarcopenia and cachexia. Despite differences in their pathophysiology, it is believed that both conditions are likely to respond to drugs that increase muscle mass and muscle strength. The current gold standard in this regard is exercise training. This article provides an overview of candidate drugs to treat muscle wasting disease that are available or in development. Drugs highlighted here include ghrelin agonists, selective androgen receptor molecules, megestrol acetate, activin receptor antagonists, espindolol, and fast skeletal muscle troponin inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., Abellan van Kan, G., Andrieu, S., Bauer, J., Breuille, D., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.01.003 · Cited by 3,256 · cited 1×
“of muscle mass [4–6].”
Self-citationBauer, J., Biolo, G., Cederholm, T., Cesari, M., Cruz-Jentoft, A. J., Morley, J. E., Phillips, S., Sieber, C., Stehle, P., Teta, D., et al. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.05.021 · Cited by 2,553 · cited 1×
“5 g/kg of highquality protein (leucine-enriched, balanced essential amino acids) to restore muscle in persons with sarcopenia [22].”
BackgroundSelf-citationGomes, A. P., Price, N. L., Ling, A. J. Y., Moslehi, J. J., Montgomery, M. K., Rajman, L., White, J. P., Teodoro, J. S., Wrann, C. D., Hubbard, B. P., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.037 · Cited by 1,482
An overview of sarcopenia: facts and numbers on prevalence and clinical impact
von Haehling, S., Morley, J. E., & Anker, S. D. (2010) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-010-0014-2 · Cited by 888 · cited 1×
“Since the initiation of the Journal of Cachexia, Sarcopenia, andMuscle in 2010 [71], there has been a remarkable increase in our knowledge regarding the treatment of muscle wasting diseases.”
BackgroundSelf-citationProtein and energy supplementation in elderly people at risk from malnutrition
Milne, A. C., Potter, J., Vivanti, A., & Avenell, A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003288.pub3 · Cited by 849 · cited 1×
“The Cochrane collaboration has shown that in malnourished older persons, protein and energy supplementation produces weight gain and reduces mortality [23].”
Srinivas-Shankar, U., Roberts, S. A., Connolly, M. J., O'Connell, M. D. L., Adams, J. E., Oldham, J. A., & Wu, F. C. W. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1251 · Cited by 629
Page, S. T., Amory, J. K., Bowman, F. D., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1933 · Cited by 566
Tieland, M., van de Rest, O., Dirks, M. L., van der Zwaluw, N., Mensink, M., van Loon, L. J. C., & de Groot, L. C. P. G. M. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.07.005 · Cited by 446 · cited 1×
“hanced in conjunction with exercise [21].”
Caminiti, G., Volterrani, M., Iellamo, F., Marazzi, G., Massaro, R., Miceli, M., Mammi, C., Piepoli, M., Fini, M., & Rosano, G. M. C. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.078 · Cited by 444 · cited 1×
“It has been shown to improve walking distance in persons with heart failure [49, 50].”
BackgroundDobs, A. S., Boccia, R. V., Croot, C. C., Gabrail, N. Y., Dalton, J. T., Hancock, M. L., Johnston, M. A., & Steiner, M. S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70055-x · Cited by 391
Cited by
Welcome to the ICD‐10 code for sarcopenia
Anker, S. D., Morley, J. E., & von Haehling, S. (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12147 · Cited by 983
Self-citationSarcopenia: A Time for Action. An SCWD Position Paper
Bauer, J., Morley, J. E., Schols, A. M. W. J., Ferrucci, L., Cruz‐Jentoft, A. J., Dent, E., Baracos, V. E., Crawford, J. A., Doehner, W., Heymsfield, S. B., et al. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12483 · Cited by 734
Self-citationMorley, J. E., Anker, S. D., & von Haehling, S. (2014) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-014-0161-y · Cited by 608
Self-citationSarcopenia: burden and challenges for public health
Beaudart, C., Rizzoli, R., Bruyère, O., Reginster, J.-Y., & Biver, E. (2014) · Archives of Public Health · doi:10.1186/2049-3258-72-45 · Cited by 495
Sarcopenia – Molecular mechanisms and open questions
Wiedmer, P., Jung, T., Castro, J. P., Pomatto, L. C. D., Sun, P. Y., Davies, K. J. A., & Grune, T. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101200 · Cited by 471
Metadata
- Authors
- Morley, J. E., von Haehling, S., & Anker, S. D.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2014-05-28
- Volume
- 5
- Issue
- 2
- Pages
- 83-87
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W2132950784
- Cited by
- 72
- References
- 17
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Are we closer to having drugs to treat muscle wasting disease? https://app.cochat.ai/papers/10.1007/s13539-014-0149-7
- The paper
- Morley, J. E., von Haehling, S., & Anker, S. D. (2014). Are we closer to having drugs to treat muscle wasting disease? Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1007/s13539-014-0149-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.